Close Menu


The firm plans to use the funds to advance its macrophage-based cell therapies, including its autologous anti-HER2 CAR macrophage treatment, CT-0508.

The funding will advance Vividion's drug discovery platform and pipeline of therapeutics targeting NRF2-mutant and NRF2-addicted cancers.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

The company will use the latest funding to begin Phase I/II trials for its lead candidate, ELI-002, in KRAS-mutated cancers.

The company will use the funds to advance its lead synthetic lethal compound CYT-0851 and launch IND-enabling studies for other drugs.

The firm will use the funds to advance its RAF-inhibitor, DAY101, which is being studied in children with BRAF-altered low-grade glioma.

The firm will use the proceeds to expand its tissue and liquid biopsy product portfolio, as well as to fund future pharma and biotechnology partnerships.

The Chinese firm will move drugs in its synthetic lethality programs, including a lead MYC inhibiting compound, into IND-enabling studies this year.

The firm's artificial intelligence-based technology uses laser editing and robotics to automate and scale stem cell production for autologous therapies.

The firm hopes to begin evaluating its irreversible menin/MLL inhibitor in clinical trials for both solid and blood cancers in by the second half of 2021.